May
Medicinal Chemistry
Strategy Meeting East Coast USA 2025
Reinvigorating Productivity in Pharmarn Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms
days
hours
minutes
seconds
What makes our strategy meetings unique?
Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.
Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.
Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.
Solutions to your Problems
We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.
Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.
Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Meet Our Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.
Bertrand Le Bourdonnec
Chief Scientific Officer HDAX TherapeuticsGovinda Bhisetti
Vice President and Head of Computational Chemistry CellarityKerren Swinger
Executive Director, Molecular Discovery Entact BioLee Fader
Vice President Congruence TherapeuticsShankar Venkatraman
Executive Director, Chemistry IFM TherapeuticsStefan Gross
Senior Director and Head of Biochemistry Servier PharmaceuticalsSee Which Topics Are Discussed at the Strategy Meeting
Transforming Drug Discovery: The Convergence of AI, Machine Learning, and Computational Sciences
Roundtable Tracks
1Looking into the Pivotal Role of AI in Drug Discovery
-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University
Innovative and Emerging Modalities
Challenges and solutions in the hit-tolead phase: ensuring efficacy and safety in drug development
-Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics
Chemical Biology, Targeted Protein Degradation u0026 Undruggables
Molecular Glue Targeted Protein Degradation on Undruggable targets
-Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics
Hit Identification / Lead Optimization
From Hits to Leads: Advanced Strategies and Technologies for Enhancing Drug Discovery in the Initial Phases
-Rich Heidebrecht
Vice President of Research and Development
Glycologix
Design u0026 Synthesis
Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate
-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics
Integrated Drug Discovery
Addressing the Unmet Needs in CNS Drug Discovery: New Paradigms in Target Identification and Drug Development
-Alex Nivorozhkin
Chief Scientific Officer
Cybin
Roundtable Tracks
2EXCELRA
Innovative and Emerging ModalitiesPioneering the Future: Harnessing Innovative Modalities in Medicinal Chemistry
-Zev Wisotsky
Director, Drug Discovery New Modality Solutions
Revvity Signals
REVVITY SIGNALS
Chemical Biology, Targeted Protein Degradation u0026 UndruggablesTargeted Protein Degradation
-Dr. Tao Guo
SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management
WuXi AppTec
WuXi AppTec
Hit Identification / Lead OptimizationLead Optimisation for bRO5 Molecules
-Vicky Steadman
Vice President Business Development and Integrated Partnerships
Sai Life Sciences
SAI LIFE
Design u0026 SynthesisImproving Efficiency in Design and Synthesys
-Kelly Barret
Director of Discovery Business Development
Sai Life Sciences
SAI LIFE
Integrated Drug DiscoverySponsor
Roundtable Tracks
3The application of Generative Design to advance drug discovery projects
-Jeremy Edmunds
Executive Director Immunology Chemistry
AbbVie
Innovative and Emerging Modalities
Strategic Innovations in Medicinal Chemistry: New Paradigms for Hit Identification and Lead Refinement
-Brian Sparling
Director, Head of Medicinal Chemistry
Accent Therapeutics
Chemical Biology, Targeted Protein Degradation u0026 Undruggables
Exploring the Current Formulation Challenges in Undruggable Leads
-Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics
Hit Identification / Lead Optimization
H2LOptimization: Oral Small Molecule Agonists/Activators
-Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics
Design u0026 Synthesis
Transforming the Future of Drug Discovery: Integrative Design and Synthesis Approaches in Medicinal Chemistry for Novel Therapeutics
-Allen Hopper
VP Drug Discovery
Lucy Therapeutics
Integrated Drug Discovery
RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches
-Jennifer Petter
Founder & CSO
Arrakis Therapeutics
Application of High Throughput Experimentation and Flow Chemistry to Accelerate Drug Discovery
Roundtable Tracks
4Leveraging Generative Modeling to Accelerate Drug Discovery – What are current state-of-art technologies?
-Muneto Mogi
Global Head, Global Discovery Chemistry
Novartis Institutes for BioMedical Research (NIBR)
Innovative and Emerging Modalities
Revolutionizing Healthcare: How Small Molecules are Shaping the Future of Emerging Therapeutic Modalities
-Bruce Ellsworth
Head of Oncology East & BBRC Medicinal Chemistry
Bristol Myers Squibb
Chemical Biology, Targeted Protein Degradation u0026 Undruggables
Unraveling Protein Targets in Disease: Proteomic Approaches to Drug Development
-Monica Schenone
Senior Director, Head Of Chemical Biology and Proteomics
Pfizer
Hit Identification / Lead Optimization
The Evolution of Hit-to-Lead Paradigms: Combining Traditional Approaches with Modern Innovations in Small Molecule Research
-Blaise Lippa
Chief Scientific Officer
Morphic Therapeutics
Design u0026 Synthesis
Integrated Drug Discovery
Integrating DEL Informatics for Accelerated Drug Discovery: Challenges and Solutions
-Ken Lind
Senior Director, Head of Chemical Computing Sciences
Jnana Therapeutics
Reasons To Attend the Strategy Meeting
Discussions on the advancements in targeted protein degradation andrnpushing past its boundaries.
Leveraging Artificial Intelligence and Machine Learning in accelerating therndevelopment of new drugs
Discuss approaches to further understand the interactions of undruggablerntargets and different Protein Degraders such as PROTACs, Molecular Glues,rnetc
Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more
Event Gallery
Press play to hear what your colleagues had to say...
Hotel & Venue
Le Méridien Boston Cambridge
Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.
Hotel Details Maps & Direction ParkingHere To Help
Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.